MedTrace Logo

Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy

NCT04134429 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-07-08

Study results available
· View outcomes & findings →

Summary

In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied. Feasibility is assessed by the number of patients wearing the device on seven consecutive days for at least 18h/day, what will be measured by monitored heart rate. Study duration for each participant is 14 days.

Conditions

Interventions

DEVICE

Everion

The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Eva Brack, MD-PhD · Pediatric Hematology/Oncology, Inselspital, Bern University Hospital

  • Christa Koenig, MD · Pediatric Hematology/Oncology, Inselspital, Bern University Hospital

Eligibility

Min Age
1 Month
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2020-01-13
Completion
2020-01-13

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04134429 on ClinicalTrials.gov